Drug Trial Radar · NCT05457283
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 8, 2022
Primary completion
Aug 7, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can help improve kidney function by reducing the activity of the renin-angiotensin-aldosterone system (RAAS). The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can impair the ability of the kidneys to work properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system. The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB. So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function. The main purpose of this study is to learn how safe the treatment is when used of finerenone in addition to an ACEI or ARB in long-term. To see how safe the treatment is, the study team will collect information on medical problems which are also known as "treatment emergent adverse events" (TEAEs). And they will also collect levels of an electrolyte called potassium in the blood by taking blood samples, and measure blood pressure during the study. The secondary purpose of this study is to learn how well long-term use of finerenone can reduce the amount of protein in the participants' urine and benefit kidney function when taken with standard of care. To see how the treatment works, the study team will collect participants' urine samples to assess urinary albumin-to-creatinine ratio (UACR) and urinary protein-to-creatinine ratio (UPCR), which are important assessments for calculating the level of protein in the urine. Researchers will also collect blood samples to analyze serum creatinine and calculate estimated glomerular filtration rate (eGFR). A significant decline in eGFR indicates worsening kidney function. The study will include participants who had previously participated in FIONA study (NCT05196035). The participants will be aged from 1 year up to 18 years. The participants will be in the study for approximately 19 months. They will take study treatment for up to 18 months and will be follow up for 1 month. During this period, at least 12 visits are planned for patients who newly start finerenone, and at least 8 visits for patients who already received finerenone. In the visit, the study team will: * have their blood pressure, heart rate, temperature, height and weight measured * have blood and urine samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart) * answer questions about their medication and whether they have any adverse events, or have their parents or guardian's answer * answer questions about how they are feeling, or have their parents or guardian's answer * answer question about how they like the study medication, or have their parents or guardian's answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The doctors will check the participants' health about 30 days after the participants take their last treatment.
Conditions
- Chronic Kidney Disease
- Proteinuria
- Children
Interventions
Finerenone (Kerendia, BAY94-8862)Drug
Finerenone in different doses, treatment duration will be 540 ±7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse event (TEAEs)Time frame: Up to 550 days
- Change in serum potassium levels from baseline to Day 540±7Time frame: Up to 547 days
- Change in systolic blood pressure (SBP) from baseline to Day 540±7Time frame: Up to 547 days
Locations
151 sites in 32 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital | Main - Transplant Department
Phoenix, Arizona · Withdrawn
Cedars-Sinai Samuel Oschin Cancer Center
Los Angeles, California · Withdrawn
Lucille Packard Children's Hospital Stanford - Pediatric Nephrology
Palo Alto, California · Active not recruiting
Rady Children's Hospital San Diego - Cardiology
San Diego, California · Withdrawn
Children's National Hospital - Nephrology
Washington D.C., District of Columbia · Withdrawn
Memorial Transplant Institute - Pediatric Nephrology
Hollywood, Florida · Withdrawn
Emory University Hospital/Children's Healthcare of Atlanta - Nephrology
Atlanta, Georgia · Withdrawn
University of Iowa Health Care Medical Center - Nephrology
Iowa City, Iowa · Withdrawn
The Charlotte R. Bloomberg Children's Center Building - Nephrology
Baltimore, Maryland · Active not recruiting
Boston Children's Hospital - Main Campus - Nephrology
Boston, Massachusetts · Withdrawn
Children's Mercy Hospital Kansas City - Nephrology
Kansas City, Missouri · Withdrawn
Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension
Cincinnati, Ohio · Withdrawn
Cleveland Clinic | Pediatric Nephrology
Cleveland, Ohio · Completed
OHSU Doernbecher Children's Hospital - Neurology
Portland, Oregon · Withdrawn
Children's Hospital of Philadelphia - Nephrology
Philadelphia, Pennsylvania · Withdrawn
University Hospital - San Antonio - Pediatric Nephrology
San Antonio, Texas · Withdrawn
Eccles Primary Children's Outpatient Services - Nephrology
Salt Lake City, Utah · Active not recruiting
Seattle Children's Hospital - Nephrology
Seattle, Washington · Withdrawn
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Active not recruiting
Hospital de Pediatría Juan P. Garrahan
Buenos Aires, Argentina · Withdrawn
Hospital General de Ninos Pedro de Elizalde | Nephrology Department
Buenos Aires, Argentina · Active not recruiting
Hospital General de Ninos Ricardo Gutierrez | Pediatric Nephrology Department
Buenos Aires, Argentina · Recruiting
Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
San Luis, Argentina · Active not recruiting
Clinica de Nefrologia, Urologia y Enfermedades Cardiovascualares | Santa Fe, Argentina
Santa Fe, Santa Fe Province, Argentina · Withdrawn
Queensland Children's Hospital
South Brisbane, Queensland, Australia · Active not recruiting
Monash Children's Hospital
Clayton, Victoria, Australia · Withdrawn
Royal Children's Hospital Melbourne
Parkville, Victoria, Australia · Recruiting
Uniklinikum Salzburg - Landeskrankenhaus
Vienna, State of Vienna, Austria · Withdrawn
Universitätsklinikum AKH Wien
Vienna, State of Vienna, Austria · Withdrawn
Medizinische Universität Graz, Landeskrankenhaus-Universitätsklinikum Graz
Graz, Styria, Austria · Withdrawn
Kepler Universitätsklinikum Campus IV
Innsbruck, Tyrol, Austria · Completed
CHC Montlégia - Pediatrics
Liège, Belgium · Withdrawn
Huderf / Ukzkf
Brussels, Brussels Capital, Belgium · Withdrawn
CU Saint-Luc/UZ St-Luc
Brussels, Brussels Capital, Belgium · Withdrawn
UZ Gent
Ghent, East Flanders, Belgium · Active not recruiting
UZ Gasthuisberg - Pediatric Nephrology
Leuven, Flemish Brabant, Belgium · Completed
Hospital Infantil Sabará - Instituto PENSI - Pesquisa e Ensino em Saúde Infantil
São Paulo, Brazil · Withdrawn
Instituto da Crianca e do Adolescente
São Paulo, Brazil · Not yet recruiting
Hospital PUC-Campinas | Centro de Pesquisa Clínica Sao Lucas
São Paulo, Brazil · Recruiting
Santa Casa de Misericórdia de Belo Horizonte
São Paulo, Brazil · Recruiting
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.